AZ cuts late-stage IL-23 drug due to trial delays, competitive landscape

Smart move, but could've been done earlier. It highlights two things:

1. There's always a tendency to keep a program alive for too long, even at an experienced drug developer at AZ. Fortunately with AZ-sized budget, it's just another tough break, but for startups dragging your feet to kill a program that has no differentiation could mean bankruptcy

2. Recruitment is just really tough in IBD, especially when you already have some effective drugs in the same class

https://endpts.com/astrazeneca-cuts-late-stage-il-23-drug-due-to-trial-delays-competitive-landscape/